Tags

Type your tag names separated by a space and hit enter

Homocysteine: a biomarker in neurodegenerative diseases.
Clin Chem Lab Med. 2011 Mar; 49(3):435-41.CC

Abstract

Diseases of the central nervous system are found in patients with severe hyperhomocysteinemia (HHcy). Epidemiological studies show a positive, dose-dependent relationship between mild-to-moderate increases in plasma total homocysteine concentrations (Hcy) and the risk of neurodegenerative diseases, such as Alzheimer's disease, vascular dementia, cognitive impairment or stroke. HHcy is a surrogate marker for B vitamin deficiency (folate, B12, B6) and a neurotoxic agent. The concept of improving the patient's clinical outcome by lowering of Hcy with B vitamins seems to be attractive. Recent B vitamin supplementation trials demonstrated a slowing of brain atrophy and improvement in some domains of cognitive function. Meta-analysis of secondary prevention trials showed that B vitamins supplementation caused a decrease in plasma Hcy and a trend for lowering the risk of stroke. HHcy is common in elderly people. Therefore, it seems prudent to identify B vitamin deficient subjects and to ensure sufficient vitamin intake. Therefore, recent evidence supports the role of Hcy as a potential biomarker in age-related neurodegenerative diseases.

Authors+Show Affiliations

Department of Clinical Chemistry, Medical School, Saarland University, Homburg, Germany. kchwher@uks.euNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21388339

Citation

Herrmann, Wolfgang, and Rima Obeid. "Homocysteine: a Biomarker in Neurodegenerative Diseases." Clinical Chemistry and Laboratory Medicine, vol. 49, no. 3, 2011, pp. 435-41.
Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med. 2011;49(3):435-41.
Herrmann, W., & Obeid, R. (2011). Homocysteine: a biomarker in neurodegenerative diseases. Clinical Chemistry and Laboratory Medicine, 49(3), 435-41. https://doi.org/10.1515/CCLM.2011.084
Herrmann W, Obeid R. Homocysteine: a Biomarker in Neurodegenerative Diseases. Clin Chem Lab Med. 2011;49(3):435-41. PubMed PMID: 21388339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine: a biomarker in neurodegenerative diseases. AU - Herrmann,Wolfgang, AU - Obeid,Rima, PY - 2011/3/11/entrez PY - 2011/3/11/pubmed PY - 2011/7/28/medline SP - 435 EP - 41 JF - Clinical chemistry and laboratory medicine JO - Clin Chem Lab Med VL - 49 IS - 3 N2 - Diseases of the central nervous system are found in patients with severe hyperhomocysteinemia (HHcy). Epidemiological studies show a positive, dose-dependent relationship between mild-to-moderate increases in plasma total homocysteine concentrations (Hcy) and the risk of neurodegenerative diseases, such as Alzheimer's disease, vascular dementia, cognitive impairment or stroke. HHcy is a surrogate marker for B vitamin deficiency (folate, B12, B6) and a neurotoxic agent. The concept of improving the patient's clinical outcome by lowering of Hcy with B vitamins seems to be attractive. Recent B vitamin supplementation trials demonstrated a slowing of brain atrophy and improvement in some domains of cognitive function. Meta-analysis of secondary prevention trials showed that B vitamins supplementation caused a decrease in plasma Hcy and a trend for lowering the risk of stroke. HHcy is common in elderly people. Therefore, it seems prudent to identify B vitamin deficient subjects and to ensure sufficient vitamin intake. Therefore, recent evidence supports the role of Hcy as a potential biomarker in age-related neurodegenerative diseases. SN - 1437-4331 UR - https://www.unboundmedicine.com/medline/citation/21388339/Homocysteine:_a_biomarker_in_neurodegenerative_diseases_ L2 - https://www.degruyter.com/document/doi/10.1515/CCLM.2011.084 DB - PRIME DP - Unbound Medicine ER -